This article focuses on the potential use of CBD as a therapeutic for the cardiovascular system, a field where CBD has been theorised to be beneficial due to its antioxidant and anti-inflammatory properties. Other studies have shown that CBD protects against the vascular damage caused by a high glucose environment, inflammation or the induction of type 2 diabetes in animal models and reduces the vascular hyperpermeability associated with such environments.
In the heart, in vivo CBD treatment protects against ischaemia-reperfusion damage and against cardiomyopathy associated with diabetes. Similarly, in a different model of ischaemia-reperfusion, CBD has been shown to reduce infarct size and increase blood flow in animal models of stroke, sensitive to 5HT1A receptor antagonism.
The effect of CBD on the cardiovascular system under physiological conditions appears to be negligible, which confirms a good safety profile of this cannabinoid. In experimental pathological conditions, such as hypertension, heart diseases, stroke, neonatal hypoxia-ischemia, diabetes or hepatic and renal ischemia/reperfusion injury, the protective effect of CBD associated with its anti-inflammatory, antioxidant, antiapoptotic, vasculoprotective, cardioprotective or neuroprotective effects is often revealed. Despite its vasodilatory properties, CBD has not been demonstrated to exhibit hypotensive action in animal models of hypertension. However, this compound might lower stress-induced increases in blood pressure in both humans and animals.
Goodbody has no association with the organisation that conducted this research and is not in a position to validate the research methods, results or conclusions of the published article. It is provided for awareness of research available that may be of interest only. Any reader should read a range of articles and research to have a balanced and informed view.